Healthcare / BiotechnologyNasdaqCM
$1.49
-0.05 (-3.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-82.4M · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$72M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-122.3%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-91.0M · FCF $-32.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | $41.1M | $10.9M | $11.5M | $16.8M | $20.6M |
| Net Income | $-91.0M | $-91.0M | $-24.3M | $-97.2M | $-76.2M | $-32.4M | $-6.3M | $-4.6M | $-6.6M | $-11.9M | $-14.8M | $-14.1M | $-12.4M | $31.5M | $-3.4M | $-2.6M | $-12.0M | $-3.5M |
| EBITDA | $-95.2M | $-95.2M | $-141.1M | $-105.8M | $-80.2M | — | $-6.4M | $-4.9M | $-6.6M | $-11.9M | $-14.9M | $-14.2M | $-12.4M | — | $-3.8M | $-3.4M | $-13.5M | $-6.5M |
| EPS | -1.88 | -1.88 | -1.46 | -2.32 | -1.90 | -0.82 | — | — | — | — | — | -2.17 | -1.89 | 4.90 | -0.56 | -0.42 | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | 76.3% | -35.8% | -30.6% | -81.5% | -32.8% |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | 76.7% | -31.6% | -22.8% | -71.5% | -16.9% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | — | — | — | — | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.19 | 2.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-32.8M | $-32.8M | $-117.0M | $-82.4M | $-80.2M | $-52.4M | — | $-2.5M | — | — | $-12.3M | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | -122.3% | -122.3% | -16.7% | -70.7% | -33.5% | -12.8% | -6.9% | -21.0% | -33.4% | -122.8% | -79.7% | -48.2% | -30.9% | 65.3% | -26.2% | -5.9% | -36.5% | -3.2% |
| Valuation | ||||||||||||||||||
| P/B | 0.97 | 0.97 | 0.92 | 7.25 | 5.05 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | — | — | — | — | 277.6% | -5.2% | -31.7% | -18.3% | — |
| EPS Growth | -28.8% | -28.8% | 37.1% | -22.1% | — | — | — | — | — | — | — | -14.8% | -138.6% | 975.0% | -33.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.46 → -1.88
Residual
-25.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.